Results	O
from	O
human	O
in	O
vitro	O
metabolism	O
studies	O
and	O
nonclinical	O
studies	O
show	O
that	O
REVLIMID	B-Brand
(	O
lenalidomide	B-Drug
)	O
is	O
neither	O
metabolized	O
by	O
nor	O
inhibits	O
or	O
induces	O
the	O
cytochrome	O
P9	O
pathway	O
suggesting	O
that	O
lenalidomide	B-Drug
is	O
not	O
likely	O
to	O
cause	O
or	O
be	O
subject	O
to	O
P9	O
-	O
based	O
metabolic	O
drug	O
interactions	O
in	O
man	O
.	O
      
Interacts	O
with	O
valproic	B-Drug
acid	I-Drug
      
This	O
may	O
result	O
in	O
severe	O
ventricular	O
arrhythmia	O
typically	O
torsades	O
de	O
pointe	O
.	O
      
However	O
in	O
clinical	O
studies	O
the	O
consequences	O
of	O
concomitant	O
irbesartan	B-Drug
on	O
the	O
pharmacodynamics	O
of	O
warfarin	B-Drug
were	O
negligible	O
.	O
      
Administration	O
of	O
a	O
9	O
g	O
bolus	O
followed	O
by	O
9	O
to	O
9	O
g	O
/	O
hr	O
should	O
achieve	O
and	O
sustain	O
plasma	O
levels	O
of	O
9	O
mg	O
/	O
mL	O
.	O
      

      
